// App-Quantinova.ai

OT1-02-02 : A pilot study to examine the feasibility of measuring CTC and inflammatory biomarker changes resulting from atorvastatin as adjuvant therapy in TNBC and TN-IBC patients with residual disease after neoadjuvant chemotherapy

Researchers

Presenter

  • Angela Alexander

Principal Investigators

  • Takeo Fujii

  • Michael C Stauder

  • Wendy A Woodward

  • James M Reuben

  • Yu Shen

  • Diane Liu

  • Sangeetha M Reddy

  • Vicente Valero

  • Susan C Gilchrist

  • Bora Lim

  • Anthony Lucci

  • Naoto T Ueno

  • Carlos H Barcenas

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Atorvastatin

  • Capecitabine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved